JP2016504400A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504400A5
JP2016504400A5 JP2015552060A JP2015552060A JP2016504400A5 JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5 JP 2015552060 A JP2015552060 A JP 2015552060A JP 2015552060 A JP2015552060 A JP 2015552060A JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552060A
Other languages
English (en)
Japanese (ja)
Other versions
JP6276289B2 (ja
JP2016504400A (ja
Filing date
Publication date
Priority claimed from GBGB1300435.3A external-priority patent/GB201300435D0/en
Application filed filed Critical
Publication of JP2016504400A publication Critical patent/JP2016504400A/ja
Publication of JP2016504400A5 publication Critical patent/JP2016504400A5/ja
Application granted granted Critical
Publication of JP6276289B2 publication Critical patent/JP6276289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552060A 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 Active JP6276289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300435.3A GB201300435D0 (en) 2013-01-10 2013-01-10 Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
GB1300435.3 2013-01-10
PCT/EP2014/050422 WO2014108520A1 (en) 2013-01-10 2014-01-10 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

Publications (3)

Publication Number Publication Date
JP2016504400A JP2016504400A (ja) 2016-02-12
JP2016504400A5 true JP2016504400A5 (enExample) 2017-01-05
JP6276289B2 JP6276289B2 (ja) 2018-02-07

Family

ID=47757796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552060A Active JP6276289B2 (ja) 2013-01-10 2014-01-10 ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用

Country Status (21)

Country Link
US (4) US9682943B2 (enExample)
EP (2) EP3115357B1 (enExample)
JP (1) JP6276289B2 (enExample)
KR (1) KR102166665B1 (enExample)
CN (1) CN105189452B (enExample)
AU (2) AU2014204831C1 (enExample)
CA (1) CA2896976C (enExample)
DK (1) DK2943467T3 (enExample)
ES (2) ES2831453T3 (enExample)
GB (1) GB201300435D0 (enExample)
HR (1) HRP20161208T1 (enExample)
HU (1) HUE030848T2 (enExample)
IL (1) IL239629B (enExample)
LT (1) LT2943467T (enExample)
MX (1) MX370491B (enExample)
PL (1) PL2943467T3 (enExample)
PT (1) PT2943467T (enExample)
RS (1) RS55185B1 (enExample)
RU (1) RU2654910C2 (enExample)
SI (1) SI2943467T1 (enExample)
WO (1) WO2014108520A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
WO2014138298A1 (en) 2013-03-05 2014-09-12 University Of Chicago Treatment of demyelinating disorders
EP3164123B1 (en) * 2014-07-02 2020-05-20 InFlectis BioScience Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
CN107709291B (zh) 2015-04-08 2021-03-12 医疗研究局 抑制剂及其应用
US9501793B1 (en) * 2015-06-04 2016-11-22 Herofi, Inc. Archetecture and associated methodology for data standardization and utilization in retail industry applications
EP3328369A1 (en) * 2015-07-31 2018-06-06 InFlectis BioScience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
US11166464B2 (en) * 2017-03-06 2021-11-09 The United States Of America, As Represented By The Secretary Of Agriculture Self-assembled active agents
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
CN113072467B (zh) * 2021-03-24 2022-04-12 南方医科大学 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用
WO2024105168A1 (en) 2022-11-18 2024-05-23 Inflectis Bioscience Novel combinations useful for the treatments of als
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications
AU2024234557A1 (en) * 2023-03-16 2025-10-30 Kyoto Prefectural Public University Corporation Sephin1 and related compounds for the treatment of diseases and disorders amenable to treatment by ampk activation and/or chop inhibition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223491A (en) 1967-10-13 1971-02-24 American Home Prod Guanidines
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
SE7607653L (sv) 1976-07-05 1978-01-06 Haessle Ab Substituerade triazoler
CA2113817A1 (en) * 1991-08-27 1993-02-04 Jerry R. Colca A method for treatment of metabolic disorders
DE793646T1 (de) * 1994-11-23 1999-12-30 Pharmacia & Upjohn Co., Kalamazoo Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus
US6335339B1 (en) 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AU7802700A (en) 1999-10-06 2001-05-10 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
FR2812812B1 (fr) 2000-08-08 2002-10-11 Philippe Gorny Medicament destine notamment a combattre les dysfonctions sexuelles
MXPA06003276A (es) * 2003-09-25 2006-06-08 Acadia Pharm Inc Tratamiento de dolor neuropatico con agonistas de receptor de neuropeptido ff 2.
CN1875271A (zh) * 2003-09-25 2006-12-06 阿卡蒂亚药品公司 用神经肽ff受体2激动剂治疗神经痛
EP1908464A1 (en) * 2006-10-04 2008-04-09 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases
ATE429910T1 (de) * 2006-10-04 2009-05-15 Centre Nat Rech Scient Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen
WO2008091681A2 (en) 2007-01-23 2008-07-31 Housey Gerard M Theramutein modulators
WO2011039735A2 (en) 2009-10-02 2011-04-07 Consiglio Nazionale Delle Ricerche Compounds with ddx3 inhibitory activity and uses thereof
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
HUE030368T2 (en) 2010-07-20 2017-05-29 Vestaron Corp Insecticide triazines and pyrimidines
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases

Similar Documents

Publication Publication Date Title
JP2016504400A5 (enExample)
RU2015127827A (ru) Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков
JP2017509586A5 (enExample)
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
JP2017071634A5 (enExample)
JP2016506960A5 (enExample)
SI3009431T1 (en) 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer
JP2016505637A5 (enExample)
JP2014521688A5 (enExample)
JP2013537203A5 (enExample)
JP2016503797A5 (enExample)
JP2016506961A5 (enExample)
PE20141282A1 (es) Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2017533968A5 (enExample)
JP2013533879A5 (enExample)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
JP2014511891A5 (enExample)
JP2016506962A5 (enExample)
JP2016513130A5 (enExample)
JP2017504635A5 (enExample)
JP2016505614A5 (enExample)
JP2016507575A5 (enExample)
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JP2016531126A5 (enExample)
JP2015500842A5 (enExample)